Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria

Yi-Fu Hou, MD, Bo Li, MD, Yong-Gang Wei, MD, Jia-Yin Yang, MD, Tian-Fu Wen, MD, Ming-Qing Xu, MD, L.V.-Nan Yan, MD, and Ke-Fei Chen, MD

Abstract: Microvascular invasion (MVI) is a strong risk factor for patients with hepatocellular carcinoma (HCC) meeting the Milan criteria and who have received curative hepatectomy. The relevance of a second hepatectomy in patients with MVI-positive recurrent HCC remains controversial.

We had 329 cases of HCC hepatectomy meeting the Milan criteria and compared data on patient demographics, liver function, and tumor pathology between MVI-positive and MVI-negative group. We analyzed potential risk factors of overall survival (OS) and disease-free survival (DFS). Furthermore, newly developed pathological features following the second hepatectomy were also analyzed.

The median OS and DFS were significantly superior in the MVI-negative group than in the MVI-positive group, 61 (10–81) months versus 49 (11–82) months (P < 0.01) and 41 (7–75) versus 13 (3–69) months (P < 0.01), respectively. The presence of MVI and a total tumor diameter >3 cm were independent risk factors associated with both OS and DFS. Overall survival was significantly improved by a second hepatectomy in the MVI-positive group compared with the original MVI-positive group, 60 (26–82) versus 49 (11–82) months, respectively. This was now comparable to the MVI-negative group, 60 (26–82) versus 61 (10–81) months (P = 0.72). A second hepatectomy was consistently associated with better survival in the MVI-negative group as compared to the MVI-positive group.

A second hepatectomy improves survival in patients with MVI HCC meeting the Milan criteria. The biology of MVI may change following a second hepatectomy. The absence of MVI is a good prognostic sign for patients undergoing second hepatectomy.

(Medicine 94(48):e2070)

INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common primary malignant focal liver lesion in the world. It is the sixth most common cancer and the third most common cause of cancer-related death. In China, chronic infection with hepatitis B is the strongest risk factor for HCC. There are 93 million hepatitis B carriers in China and their risk of developing HCC is 200 times higher than that of noncarriers. According to most clinical guidelines, liver resection and liver transplantation represent curative treatments for early stage HCC or HCC meeting the Milan criteria, namely, ≤3 nodules, ≤3 cm, or a single HCC ≤5 cm without macrovascular invasion (MaVI). A 5-year overall survival (OS) >70% and a tumor recurrence in <10% of all cases who receive liver transplantation have been reported. However, because of the extremely limited number of organ donors in China, transplantation in patients with HCC meeting the Milan criteria is usually not an option. Therefore, hepatectomy remains the only treatment option.

Unfortunately, hepatectomy is associated with a relatively high risk of recurrence despite multiple advances in surgical techniques. It has been reported that HCC recurs in 70% to 80% of all cases over the 5 years following curative hepatectomy. Tumor biological characteristics such as pathologically verified MVI has been recognized as an important factor influencing survival. Despite the rigorous requirements of the Milan criteria, the existence of MVI cannot be detected before surgery. According to previous studies, the incidence of MVI depends on various tumor characteristics and is closely associated with tumor diameter. The survival impact of MVI in patients meeting the Milan criteria following HCC hepatectomy is unclear. Moreover, the role of MVI in recurrent HCC is also uncertain because there are few studies on the clinical significance of MVI in patients with recurrent HCC undergoing a second hepatectomy. Whether a second hepatectomy improves survival remains unclear. The clinical significance of MVI changing after a second hepatectomy warrants clarification.

The present retrospective study was performed to analyze the long-term survival in patients meeting the Milan criteria after hepatectomy and how posthepatectomy MVI status affects survival.

MATERIALS AND METHODS

Patients

From January 2007 to December 2012, a total of 970 HCC patients received hepatectomy in West China Hospital of...
Our institutional review board approved the study. Following hepatectomy to be the end points of our study. Time, postrecurrence survival, and postoperative complications were the exclusion criteria were as follows: (1) margin HCC-positive of the initial resection; (2) a previous history of other malignancy; (3) pathological confirmation of mixed-type HCC with intrahepatic cholangiocellular carcinoma. We included OS, disease-free survival (DFS) time, postrecurrence survival, and postoperative complications (PC) following hepatectomy to be the end points of our study. Our institutional review board approved the study.

Hepatectomy
Preoperative assessment was essential for patients who were about to receive partial hepatectomy and included blood routine tests, liver function tests, serum alpha-fetal protein (AFP) tests, indocyanine green (ICG) clearance tests, and 3-phase-enhanced computed tomography (CT), or magnetic resonance imaging (MRI) scans. A 15-min ICG retention rate ≤15% for major hepatectomy (≥3 segmentectomies), ≤20% for minor hepatectomy (≤2 segmentectomies), and a remnant liver volume ≥50% of the total liver volume were the baseline requirements for hepatectomy. All patients were subject to open surgery. We used Cavitron Ultrasonic Surgical Aspirator or clamp crushing as the 2 principal methods for parenchymal dissection. Continuous/intermittent selective hepatic vascular occlusion was applied to control surgical blood loss. We used intraoperative ultrasonography to guide our resection margin and any additional nodules missed by preoperative imaging were also removed. A margin of nontumoral hepatic tissue ≥5 mm was required and ≥1 cm was preferred. We considered anatomic resection preferential to nonanatomic resection.

Pathological Examination
The histological grade was based on the criteria of the Edmondson–Steiner classification. Therefore, we defined grade I and grade II as well-differentiated and grade III and grade IV as poor-differentiated tumors. Microvascular invasion was defined as tumor embolus detected by microscopy in the hepatic veins, portal system, and/or lymphatic ducts. Satellite lesions were defined as small lesions within 2 cm of the HCC mass. Our pathological diagnostic algorithm followed the Chinese guidelines for standardized pathological diagnosis of HCC. All tumor and nontumoral tissues were examined microscopically.

Hospitalization and Follow-up
Data on total hospital stay were available through the hospital digital health care system. To compare postoperative complications, we used the Clavien classification to classify the severity. After initial hepatectomy, the patients were followed up at our outpatient clinic at intervals of 1 to 3 months until recurrence was confirmed. With the help of the local police security system, we could track every patient lost to follow-up. Blood routine tests, liver function tests, serum AFP tests, and abdominal ultrasonography were carried out at each follow-up.

When suspicious nodules were found or persistent elevated AFP levels were observed, enhanced CT or MRI would be applied to the patient for confirmation. The diagnosis of recurrent HCC depended on a 3-phase-enhanced imaging study showing typical features of HCC (contrast uptake in the arterial phase followed by rapid washout in the venous phase).

Treatment of Recurrent HCC
When HCC recurrence was confirmed, repeated hepatectomy was still the first choice if the patient had sufficient hepatic reserve. Radiofrequency ablation (RFA) was used as a substitutional option for resection when the recurrent tumor diameter was within 2 cm. Transarterial chemoembolization (TACE) was the palliative therapy therapeutic option for intrahepatic HCC management. Chemotherapy and radiation were applied to some patients with extrahepatic HCC lesions. For patients with uncontrollable HCC or bad general condition, best supportive care was carried out. When recurrence occurred after the second hepatectomy, the treatment choice followed the description mentioned above.

Statistical Analysis
Baseline comparisons between the 2 groups were analyzed with Student’s t test for continuous variables, the Mann–Whitney U test for nonparametric variables, and the chi-square test for categorical variables. Fisher’s exact test was applied to compare PC. Cumulative OS rates between the 2 groups were analyzed using the Kaplan–Meier survival curves and tested using the log-rank test. Univariate and multivariate Cox proportional hazard models were used to identify prognostic risk factors. Probability (P) values < 0.05 were considered statistically significant. All analyses were performed with SPSS version 21.0 (IBM SPSS Inc, Chicago, IL).

RESULTS
Patient Demographics
Among 960 cases of HCC hepatectomy, 329 patients who met the inclusion and exclusion criteria were retrospectively enrolled. There were 102 (31.0%) patients in the MVI-positive group (test group) and 227 (69.0%) patients in the MVI-negative group (control group). The general patient characteristics such as age, male: female ratio, blood test results, and Child–Pugh status were comparable (Table 1). In the test group, patients presented with similar tumor status as compared with the control group (size: 3.5 [2–6] cm vs 4 [1–6] cm and number: 1 [1–3] vs 1 [1–3] [P = 0.99 and P = 0.73, respectively]). Serum AFP levels were significantly higher in the test group as compared with the control group (160.1 [1.7–1210.0] ng/mL vs 18.7 [1.8–1210.0] ng/mL [P < 0.01]). Other parameters of pathological character such as satellite lesions were comparable (11.8% [12/102] vs 11.5% [26/227] [P = 0.94]), and the ratio of poorly differentiated cells was significantly higher in the test group than that in the control group (32.4% [33/102] vs 16.3% [37/227], P < 0.01).

Surgical Outcomes and Postoperative Hospitalization
Postoperative complications were comparable between the 2 groups. There were 57 (55.6%) cases of grade 0 events, 38 (37.5%) cases of grade I events, and 7 (6.9%) cases of grade II events in the test group and the corresponding results for the
control group were 113 cases (48.9%), 85 cases (37.4%), and 29 cases (12.7%), respectively ($P = 0.25$). No cases of severe complication or hospital-associated mortality were recorded in any of the groups. Median lengths of hospitalization were comparable between the test and control groups, 8 (4–21) days versus 9 (4–20) days ($P = 0.62$; Table 1).

### Survival

The median follow-up time was 60 (10–82) months. The median OS time and DFS in the test and control groups were 49 (11–82) months versus 61 (10–81) months and 13 (3–69) months versus 41 (7–75) ($P < 0.001$ and $P < 0.001$), respectively (Figure 1). The 1-, 3-, and 5-year DFS rates in the test group were 53.8%, 14.2%, and 11.8%, respectively. The corresponding data in the control group were 91.2%, 52.5%, and 43.6%, respectively. The 1-, 3-, and 5-year OS rates in the test group were 98.0%, 64.7%, and 34.6%, respectively. The corresponding data in the control group were 100.0%, 89.4%, and 56.4%, respectively. At the end of our study, a total of 68 deaths had been recorded in the test group. Two died of liver cirrhosis, 1 of rejection reaction after salvage transplantation, 1 of an accident, and the remaining 64 because of cancer. In the control group, there were 93 deaths; 24 died of liver cirrhosis, 1 died of chronic renal failure, and the remaining 68 deaths were attributed to cancer. By the end of the follow-up, 14 cases were recurrence-free in the test group, whereas 88 cases experienced HCC recurrence. Among the 88 cases, 45 received a second hepatectomy, 33 received TACE, 9 received RFA, and 1 received salvage transplantation. In the control group, 112 cases were recurrence-free, and 115 cases experienced HCC recurrence. Among the latter, 85 received a second hepatectomy, 18 received RFA, and 12 received TACE.

In a subgroup analysis, we compared the OS in patients who received a second hepatectomy because of HCC intrahepatic recurrence in the MVI-negative and the MVI-positive groups. The results showed a comparable outcome between the MVI-positive group and the MVI-negative group: 61 (26–82) months versus 61 (10–81) months ($P = 0.72$; Figure 2). Furthermore, we compared the different interventions used for treating recurrent HCC and found that postrecurrence OS was significantly improved after the 2nd hepatectomy as compared with RFA and TACE, 43 (10–59) months versus 32 (10–41) months and 43 (10–59) months versus 16 (6–41) months ($P = 0.01$ and $P < 0.01$, respectively (Figure 3).

For patients who received a second hepatectomy, we noticed that some had different MVI results as compared with the first hepatectomy. In total there were 11 (8.5%) MVI positive-negative shifting cases and 24 (18.5%) MVI negative–positive shifting cases. Moreover, a comparison of DFS following second hepatectomy for patients in the MVI-positive and MVI-negative groups with regard to the results of second pathological examination showed that the new MVI-

### Table 1. Patients’ Baseline Comparison the MVI-Positive Group and the MVI-Negative Group

| Factors                        | MVI Negative | MVI Positive | $P$  |
|--------------------------------|--------------|--------------|------|
| General characteristic         |              |              |      |
| Age (mean ± SD, y)             | 52.1 ± 11.9  | 52.4 ± 12.9  | 0.26 |
| Male sex (n%)                  | 81.9% (186/227) | 85.3% (87/102) | 0.45 |
| BMI (mean ± SD)                | 21.2 ± 2.6   | 20.8 ± 2.8   | 0.77 |
| HBV-DNA positive (n%)          | 36.1% (82/227) | 33.3% (34/102) | 0.62 |
| HCV Ab positive (n%)           | 2.2% (5/227)  | 2.9% (3/102)  | 0.69 |
| Child-Pugh classification      | 0.11         |              |      |
| Child-Pugh A                   | 223          | 97           |      |
| Child-Pugh B                   | 4            | 5            |      |
| WBC (10⁹/L)                    | 4.7 (3.1-10.8) | 5.1 (3.1-13.2) | 0.22 |
| PLT (10⁹/L)                    | 103 (42–259) | 113 (42–285) | 0.25 |
| TB (µmol/L)                    | 12.4 (3.5–17.1) | 12.1 (4.5–17.1) | 0.56 |
| ALB (g/L)                      | 42.7 (33.3–56.9) | 41.1 (33.5–51.8) | 0.17 |
| Tumor characteristic           |              |              |      |
| Tumor size (mean ± SD, cm)     | 4 (1–6)      | 3.5 (2–6)    | 0.99 |
| Tumor number (median, range)   | 1 (1–3)      | 1 (1–3)      | 0.73 |
| AFP level (ng/mL)              | 18.7 (1.8–1210.0) | 160.1 (1.7–1210.0) | <0.01 |
| Pathology characteristic       |              |              |      |
| Satellite positive (n%)        | 11.5% (26/227) | 11.8% (12/102) | 0.94 |
| Poor differentiation (n%)      | 16.3% (37/227) | 32.4% (33/102) | <0.01 |
| Hospitalization                |              |              |      |
| Hospitalization (range, d)     | 9 (4–20)     | 8 (4–21)     | 0.62 |
| Postoperative complications    | 0.25         |              |      |
| Grade 0                        | 113          | 57           |      |
| Grade I                        | 85           | 38           |      |
| Grade II                       | 29           | 7            |      |
| Grade III                      | 0            | 0            |      |
| Grade IV                       | 0            | 0            |      |

**AFP** = alpha fetoprotein, high AFP level was defined as >400 ng/mL, **ALB** = albumin, BMI = body mass index, HBV-DNA = positive was defined as >1000 IU/mL, HCV = Ab hepatitis C virus antibody, MaVI = macrovascular invasion, MVI = microvascular invasion, PLT = platelet, TB = total bilirubin, WBC = white blood cell.
positive group had a significantly worse outcome than the new MVI-negative group, 13 (3–28) months versus 26 (10–53) months (P < 0.01; Figure 4).

Prognostic Factors

Table 2 lists the results of univariate and multivariate analyses of prognostic factors related to OS and DFS for all study individuals. The factors significantly associated with OS identified by univariate analysis included total tumor diameter >3 cm (hazard ratio [HR] = 1.50, P = 0.01) and MVI positivity (HR = 2.02, P < 0.01). For multivariate analysis, we selected factors identified using univariate analysis with P values < 0.05 together with certain significant clinical variables. The significant risk factors related to worse OS identified using multivariate analysis were as follows: MVI positivity (HR = 2.04; 95% confidence interval [CI], 1.49–2.80; P < 0.01), and total tumor diameter >3 cm (HR = 1.49; 95% CI, 1.09–2.06; P = 0.01) (Table 2).

Prognostic factors of DFS as revealed by univariate analysis included a total tumor diameter >3 cm (HR = 1.45,
The MVI rate was 31.2%, which is surprisingly high considering the fact that the tumor is generally considered less aggressive at this early stage. Baseline comparisons showed that the MVI-positive group had almost the same tumor status and pathological results as the MVI-negative group, except for microvascular invasion. Therefore, it makes sense those MVI-positive patients present with lower differentiated tumors and higher serum AFP levels. In the survival analysis, the test group unsurprisingly showed both worse OS and DFS than the control group. In more detail, ~50% of the patients in the test group experienced HCC recurrence within the first year following hepatectomy and this proportion had reached ~80% by the third year. On the other hand, <10% of the patients in the control group experienced HCC recurrence within the first year following hepatectomy. After 3 years, this share had reached ~50%. This phenomenon may be explained by earlier studies suggesting that the presence of MVI is related to the time of HCC recurrence, which was reconfirmed by our results. According to Llovet’s classification, recurrence is defined by (1) true metastasis recurring within 2 years and (2) multicentric tumors that arise de novo in a pre-neoplastic liver. Therefore, it is not surprising that MVI is repeatedly identified as a risk factor for early HCC recurrence. Moreover, the results of our multivariate analyses showed that both total tumor diameter and MVI are the independent risk factors of OS and DFS. These results suggest that size matters in early stage HCC and special attention should be paid to both MVI and tumor burden in the management of early stage HCC.

The management of recurrent HCC is still controversial. In China, we value the importance of repeat hepatectomy, especially in patients with primary early stage HCC. In this study, second hepatectomy was chosen as the first choice for recurrent HCC. Our results showed that patients in the test group who received a second hepatectomy had a comparable survival compared to those who received partial hepatectomy. This is consistent with other studies reporting a better OS and DFS for patients with MVI who underwent repeat hepatectomy compared to those who did not receive a second hepatectomy. However, the long-term survival benefit of repeat hepatectomy in patients with MVI is still debated.

In conclusion, the findings of this study indicate that MVI is an important risk factor for recurrence and OS in patients with early stage HCC. Therefore, MVI should be considered as a critical factor when staging early stage HCC. Additionally, MVI-positive patients should be closely followed and monitored due to their increased risk of recurrence. Future studies with larger patient samples are needed to further validate these findings and to explore the potential role of MVI as a therapeutic target for HCC.

**DISCUSSION**

Hepatocellular carcinoma meeting the Milan criteria is generally considered to be early HCC with a relatively high potential for cure. According to the criteria, the 5-year mortality is expected to be <30% for patients undergoing liver transplantation. However, because of the large number of hepatitis B carriers and the extremely limited number of organ donors in China, most patients meeting the Milan criteria still receive partial hepatectomy. In this study, the estimated median survival for all the patients reached 60 months, reflecting a generally satisfying result of disease control. This result is also consistent with the data of stage A HCC of Barcelona clinic liver cancer staging system. However, despite the early stage of HCC, the estimated median progression-free survival for all patients after the curative resection was 25 (3–75) months, which was worse than the outcome of liver transplantation. Therefore, it makes sense those MVI-positive patients present with lower differentiated tumors and higher serum AFP levels. In the survival analysis, the test group unsurprisingly showed both worse OS and DFS than the control group. In more detail, ~50% of the patients in the test group experienced HCC recurrence within the first year following hepatectomy and this proportion had reached ~80% by the third year. On the other hand, <10% of the patients in the control group experienced HCC recurrence within the first year following hepatectomy. After 3 years, this share had reached ~50%. This phenomenon may be explained by earlier studies suggesting that the presence of MVI is related to the time of HCC recurrence, which was reconfirmed by our results. According to Llovet’s classification, recurrence is defined by (1) true metastasis recurring within 2 years and (2) multicentric tumors that arise de novo in a pre-neoplastic liver. Therefore, it is not surprising that MVI is repeatedly identified as a risk factor for early HCC recurrence. Moreover, the results of our multivariate analyses showed that both total tumor diameter >3 cm and MVI are the independent risk factors of OS and DFS. These results suggest that size matters in early stage HCC and special attention should be paid to both MVI and tumor burden in the management of early stage HCC.

The management of recurrent HCC is still controversial. In China, we value the importance of repeat hepatectomy, especially in patients with primary early stage HCC. In this study, second hepatectomy was chosen as the first choice for recurrent HCC. Our results showed that patients in the test group who received a second hepatectomy had a comparable survival compared to those who received partial hepatectomy. This is consistent with other studies reporting a better OS and DFS for patients with MVI who underwent repeat hepatectomy compared to those who did not receive a second hepatectomy. However, the long-term survival benefit of repeat hepatectomy in patients with MVI is still debated.

In conclusion, the findings of this study indicate that MVI is an important risk factor for recurrence and OS in patients with early stage HCC. Therefore, MVI should be considered as a critical factor when staging early stage HCC. Additionally, MVI-positive patients should be closely followed and monitored due to their increased risk of recurrence. Future studies with larger patient samples are needed to further validate these findings and to explore the potential role of MVI as a therapeutic target for HCC.
outcome to that observed in patients in the control group. Hence, second hepatectomy improves survival in HCC MVI-positive patients meeting the Milan criteria.38 Interestingly, with regard to the pattern of MVI changes following second hepatectomy, we observed 24 MVI-negative shifting cases and 11 MVI-positive shifting cases. This phenomenon of MVI shifting had a significant influence on patient survival (Figure 4). More specifically, 33/35 (94.3%) MVI-positive cases following the second hepatectomy experienced recurrence once again within 2 years (early recurrence). However, only 32/95 (33.7%) MVI-negative cases following the second hepatectomy experienced early recurrence. A possible explanation is that the 21 MVI-negative shifting cases and 11 MVI-positive shifting cases may reflect tumor phenotype differences and not tumor intrahepatic spread. We have previously shown that some early stage MVI-positive cases of HCC could show alternative results on MVI following a second hepatectomy.39 In this article, we focused on early stage HCC and obtained consistent results. For diagnostic accuracy, we value the importance of the pathological results of HCC, especially early stage HCC. Complete examination of all tumor and nontumor tissue is mandatory for small HCC. Although MVI is associated with poor patient survival, the presence of MVI-negative shifting may suggest the complete clearance of the tumor. Hence, MVI could be a sensitive marker for patient outcome—whenever MVI disappears, a better prognosis can be expected.

In the management of HCC recurrence, we find that repeat hepatectomy provides better survival than RFA and TACE. Thanks to advances in the surgical technique and perioperative management over the past few decades, repeat hepatectomy is considered safe for suitable patients.24,40 For patients with resectable recurrent HCC, repeat hepatectomy should be considered the first-line choice. However, the results of RFA and TACE in resectable HCC remain unknown because as stated in the Materials and Methods section, only those recurrent patients who were not suitable for a second hepatectomy were otherwise considered for RFA and TACE. Nevertheless, resection has been proven to be a better choice than RFA and TACE for early stage nonrecurrent HCC.30 We consider radical resection to be the best option for early stage recurrent HCC.

### TABLE 2. Univariate and Multivariate Analysis for Prognostic Factors of OS and DFS

| Factors                        | Hazard Ratio (HR) OS DFS | 95% CI                  | P       |
|--------------------------------|--------------------------|-------------------------|---------|
| **Univariate analysis**        |                          |                         |         |
| Age (y, >50 vs <50)            | 1.09                     | 0.79–1.50               | 0.60    |
|                                | 0.91                     | 0.69–1.20               | 0.49    |
| Male sex (male vs female)      | 1.22                     | 0.80–1.87               | 0.35    |
|                                | 1.10                     | 0.75–1.60               | 0.63    |
| HBV-DNA (positive vs negative) | 1.31                     | 0.95–1.81               | 0.11    |
|                                | 0.90                     | 0.67–1.21               | 0.50    |
| HCV infection (positive vs negative) | 1.19                     | 0.49–2.90               | 0.71    |
|                                | 1.14                     | 0.47–2.76               | 0.78    |
| Child-Pugh classification (B vs A) | 1.54                     | 0.68–3.48               | 0.30    |
|                                | 1.96                     | 0.77–2.18               | 0.16    |
| AFP (ng/mL, >400 vs ≤ 400)     | 0.81                     | 0.58–1.15               | 0.24    |
|                                | 1.06                     | 0.79–1.42               | 0.72    |
| Tumor diameter (cm, >3 vs ≤ 3) | 1.50                     | 1.10–2.06               | 0.01    |
|                                | 1.45                     | 1.10–1.92               | 0.01    |
| Tumor number (multi vs solitary) | 1.14                     | 0.66–1.98               | 0.63    |
|                                | 1.27                     | 0.78–2.06               | 0.33    |
| MVI (positive vs negative)     | 2.02                     | 1.48–2.77               | <0.01   |
|                                | 3.64                     | 2.74–4.84               | <0.01   |
| Satellite lesion (positive vs negative) | 1.03                     | 0.64–1.65               | 0.91    |
|                                | 1.22                     | 0.81–1.84               | 0.35    |
| Differentiation degree (high vs low) | 1.08                     | 0.74–1.58               | 0.68    |
|                                | 1.41                     | 1.02–1.95               | 0.04    |
| **Multivariate analysis**      |                          |                         |         |
| MVI (positive vs negative)     | 2.04                     | 1.49–2.80               | <0.01   |
|                                | 3.63                     | 2.72–4.84               | <0.01   |
| Tumor diameter (cm, >3 vs ≤ 3) | 1.49                     | 1.09–2.06               | 0.01    |
|                                | 1.49                     | 1.13–1.97               | 0.01    |
| AFP (ng/mL, >400 vs ≤ 400)     | 0.72                     | 0.51–1.02               | 0.17    |
|                                | 1.03                     | 0.77–1.38               | 0.86    |
| Child-Pugh classification (B vs A) | 1.22                     | 0.54–2.78               | 0.64    |
|                                | NA                       | NA                      |        |
| Differentiation degree (high vs low) | NA                       | NA                      |        |
|                                | 1.13                     | 0.81–1.56               | 0.47    |

AFP = alpha fetoprotein, high AFP level was defined as >400 ng/mL, BMI = body mass index, DFS = disease-free survival, HBV-DNA = positive was defined as >1000 IU/mL, HCV Ab = hepatitis C virus antibody, MVI = microvascular invasion, OS = overall survival, SD = standard deviation.
Our study had some limitations. The retrospective nature and the single-center status of this study limit its validity and further studies are required to confirm our results.

CONCLUSIONS
Performing a second hepatectomy is a safe and effective approach for treating intrahepatic recurrence of HCC meeting the Milan criteria. It improves survival for patients positive for MVI after the first hepatectomy. The importance of tumor MVI status following second hepatectomy should be acknowledged.

ACKNOWLEDGMENTS
This work was supported by the whole team of the liver surgery department at West China Hospital.

REFERENCES
1. de Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol. 2012;56(Suppl. 1):S75–S87.
2. Caldwell S, Park SH. The epidemiology of hepatocellular cancer from the perspectives of public health problem to tumour biology. J Gastroenterol. 2009;44(Suppl. 19):96–101.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917.
4. Masao O, Laurentius AL, Ryosuke T, et al. Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–474.
5. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2004;127:303–309.
6. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.
7. Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl). 2009;122:3–4.
8. Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226–1233.
9. Mazzaferrro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med. 1996;334:693–699.
10. Bhoori S, Sposito C, Germini A, et al. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transpl Int. 2010;23:712–722.
11. Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11–e22.
12. Lei JY, Wang WT, Yan LN. Hangzhou criteria for liver transplantation in hepatocellular carcinoma: a single-center experience. Eur J Gastroenterol Hepatol. 2014;26:200–204.
13. Cha CH, Ruo L, Fong Y, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg. 2003;238:315–321.
14. Cucchetti A, Cescon M, Ercolani G, et al. Comparison between observed survival after resection of transplantable hepatocellular carcinoma and predicted survival after listing through a Markov model simulation. Transpl Int. 2011;24:787–796.
15. Zhou Y, Sui C, Li B, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review. World J Surg Oncol. 2010;8:55.
16. Grazzi GL, Ercolani G, Pierangeli F, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001;234:71–78.
17. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–524.
18. Jonas S, Bechstein WO, Steinmüller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–1086.
19. Rodriguez-Perılvez M, Luong TV, Andreaa L, et al. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20:325–339.
20. Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850–855.
21. Cucchetti A, Piscaglia F, Griqioni AD, et al. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol. 2010;52:880–881.
22. Kim BK, Han KH, Park YN, et al. Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. J Surg Oncol. 2008;97:246–252.
23. Giulante F, Ardito F, Pinna AD, et al. Liver resection for hepatocellular carcinoma ≤3 cm: results of an Italian multicenter study on 588 patients. J Am Coll Surg. 2012;215:244–254.
24. Chan AC, Chan SC, Chok KS, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl. 2013;19:411–419.
25. Tranchart H, Chirica M, Sepulveda A, et al. Long-term outcomes following aggressive management of recurrent hepatocellular carcinoma after upfront liver resection. World J Surg. 2012;36:2684–2691.
26. Oken MM, Creech RH, Torney DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:469–465.
27. Zhou L, Rui JA, Ye DX, et al. Edmonson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg. 2008;32:1748–1756.
28. Cong WM, Bu H, Chen J, et al. The clinical guideline of the pathological diagnosis in HCC (2015 Version). J Clin Exp Pathol. 2015;21:145–151.
29. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann surg. 2004;240:205–213.
30. EASL-EORTC Clinical Practice Guidelines. Management of hepatocellular carcinoma. European association for the study of the liver, european organization for research and treatment of cancer. J Hepatol. 2012;56:908–943.
31. Kaibori M, Ishizaki M, Saito T, et al. Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg. 2009;199:39–45.
32. Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74.
33. Quaglia A, Etessami N, Sim R, et al. Vascular invasion and prognostic variability. Review of microvascular invasion in hepatocellular carcinoma: a meta-analysis. Hepatology. 2014;59:998–1007.
34. Ding T, Xu J, Zhang Y, et al. Endothelium-coated tumour clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection. Cancer. 2011;117:4878–4889.
35. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis. 2010;30:17–25.

36. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500–507.

37. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–235.

38. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.

39. Hou YF, Wei YG, Li B, et al. Microvascular invasion patterns affect survival in hepatocellular carcinoma patients after second hepatectomy. J Surg Res. 2015pii:S0022-4804(15)00745-3doi: 101016.

40. Yoshihiro M, Kiyoshi H, Junichi S. The feasibility of third of more repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg. 2014;00:1–11.